| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-01 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6843
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6813 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-24 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 |
| filingDate |
2007-10-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2010-03-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2010508248-A |
| titleOfInvention |
Use of a fusion protein targeting the ED-B fibronectin domain for the treatment of atherosclerosis |
| abstract |
The present invention relates to an antibody portion, an effector portion, and optionally one or more fusion proteins that specifically recognize ED-B fibronectin for the manufacture of a medicament for the treatment and prevention of atherosclerosis. It relates to the use of fusion proteins comprising linker (s) and / or antibody linker (s). |
| priorityDate |
2006-10-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |